Teladoc Health Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Chuck Divita

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	7.1yrs
Gemiddelde ambtstermijn bestuur	6.1yrs

Recente managementupdates

Recent updates

CEO

Chuck Divita (54 yo)

less than a year

Tenure

Mr. Charles Divita, III is CEO and Director at Teladoc Health, Inc. since June 2024. He served as Florida Combined Life Insurance Company, Inc. from 2018 to 2024. He had been Executive Vice President of Co...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Mala Murthy	Chief Financial Officer	5.4yrs	US$5.94m	0.050% € 750.4k
Michael Waters	Chief Operating Officer	2.3yrs	US$4.80m	0.045% € 685.0k
Adam Vandervoort	Chief Legal Officer & Secretary	9.8yrs	US$3.54m	0.027% € 404.6k
Charles Divita	CEO & Director	less than a year	geen gegevens	geen gegevens
George Brooks	Co-Founder	22.8yrs	geen gegevens	geen gegevens
Joseph Catapano	Senior VP & Chief Accounting Officer	less than a year	geen gegevens	geen gegevens
Nikolaos Nanis	Chief Technology Officer	no data	geen gegevens	0.044% € 659.7k
Patrick Feeley	Vice President of Investor Relations	no data	geen gegevens	geen gegevens
Andrew Turitz	Executive Vice President of Corporate Development	9.8yrs	US$2.07m	0.012% € 181.8k
Stephany Verstraete	Chief Marketing Officer & Engagement Officer	8.8yrs	US$2.01m	0.028% € 427.3k
Arnnon Geshuri	Chief People Officer	4.1yrs	geen gegevens	0.026% € 393.0k
Daniel Trencher	Chief Strategy Officer	9.8yrs	geen gegevens	0.018% € 275.3k

7.1yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 4LL is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Charles Divita	CEO & Director	less than a year	geen gegevens	geen gegevens
Thomas McKinley	Independent Director	15yrs	US$290.00k	0.023% € 341.9k
David Shedlarz	Independent Director	8.2yrs	US$294.49k	0.0086% € 129.5k
David Snow	Independent Non-Executive Chairman	10.8yrs	US$332.50k	0.069% € 1.0m
Sandra Fenwick	Independent Director	4yrs	US$280.00k	0.023% € 353.7k
Kenneth Paulus	Independent Director	7.8yrs	US$285.00k	0% € 0
Mark Smith	Independent Director	6.1yrs	US$283.00k	0.0049% € 73.1k
Catherine Jacobson	Independent Director	4.8yrs	US$280.00k	0.012% € 178.5k
J. Evans	Independent Director	1.2yrs	US$264.69k	0.0024% € 35.5k

6.1yrs

Gemiddelde duur

69yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 4LL wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.1 jaar).

Teladoc Health Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Teladoc Health, Inc. Appoints Joseph Catapano as its Senior Vice President and Chief Accounting Officer

Teladoc Health, Inc. Appoints Charles Divita, III as Director

Teladoc Health, Inc., Annual General Meeting, May 23, 2024

Teladoc Health, Inc. Announces Chief Executive Officer Changes

Insufficient new directors

Teladoc Health, Inc. Announces Resignation of Claus T. Jensen, PhD as Chief Innovation Officer Effective December 1, 2023

Recent updates

Teladoc Health, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2024

Third quarter 2024 earnings released: US$0.19 loss per share (vs US$0.35 loss in 3Q 2023)

Teladoc Health, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Teladoc Health, Inc. Appoints Joseph Catapano as its Senior Vice President and Chief Accounting Officer

Second quarter 2024 earnings released: US$4.92 loss per share (vs US$0.40 loss in 2Q 2023)

Teladoc Health, Inc. to Report Q2, 2024 Results on Jul 31, 2024

Teladoc Health, Inc.(NYSE:TDOC) dropped from Russell 1000 Dynamic Index

Teladoc Health, Inc. Releases New Data from Two Studies

Teladoc Health, Inc. Appoints Charles Divita, III as Director

Robbins Geller Rudman & Dowd LLP Announces Class Action Lawsuit against Teladoc Health, Inc

Teladoc Health, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2024

First quarter 2024 earnings released: US$0.49 loss per share (vs US$0.42 loss in 1Q 2023)

Teladoc Health, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Teladoc Health, Inc., Annual General Meeting, May 23, 2024

Teladoc Health, Inc. Announces Chief Executive Officer Changes

Full year 2023 earnings released: US$1.34 loss per share (vs US$84.60 loss in FY 2022)

No longer forecast to breakeven

No longer forecast to breakeven

Teladoc Health, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024

Teladoc Health, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Forecast to breakeven in 2026

Insufficient new directors

Teladoc Health, Inc. Announces Resignation of Claus T. Jensen, PhD as Chief Innovation Officer Effective December 1, 2023

Teladoc Health, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ending December 31, 2023

Third quarter 2023 earnings released: US$0.35 loss per share (vs US$0.45 loss in 3Q 2022)

Teladoc Health, Inc. to Report Q3, 2023 Results on Oct 24, 2023

Teladoc Health, Inc. Appoints Eric Evans to Board of Directors

New minor risk - Shareholder dilution

Teladoc Health, Inc. Provides Earnings Guidance for the Third Quarter of 2023 and Year Ending December 31, 2023

Second quarter 2023 earnings released: US$0.40 loss per share (vs US$19.22 loss in 2Q 2022)

Teladoc Health, Inc. to Report Q2, 2023 Results on Jul 25, 2023

Teladoc Health, Inc. to Report Q2, 2023 Results on Jul 25, 2023

New minor risk - Share price stability

Teladoc Health, Inc.(NYSE:TDOC) dropped from Russell 1000 Growth Index

First quarter 2023 earnings released: US$0.42 loss per share (vs US$41.58 loss in 1Q 2022)

Now 24% undervalued

CEO & Director recently sold €539k worth of stock

Full year 2022 earnings released: US$84.60 loss per share (vs US$2.73 loss in FY 2021)

Teladoc Health, Inc. to Report Q4, 2022 Results on Feb 22, 2023

Teladoc Health Launches Fully Integrated Whole-Person Care Experience with New App

Chief People Officer recently sold €63k worth of stock

Third quarter 2022 earnings released: US$0.45 loss per share (vs US$0.53 loss in 3Q 2021)

Teladoc Health, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

Teladoc Health Inc. Appoints Laizer Kornwasser as President, Enterprise Growth & Global Markets

Teladoc Health, Inc. to Report Q3, 2022 Results on Oct 26, 2022

Teladoc Health, Inc.(NYSE:TDOC) dropped from FTSE All-World Index (USD)

Chief People Officer recently sold €141k worth of stock

Second quarter 2022 earnings released: US$19.22 loss per share (vs US$0.86 loss in 2Q 2021)

Teladoc Health, Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2022

Teladoc Health, Inc. Appoints Mike Waters as Chief Operating Officer

Teladoc Health’S Integrated Chronic Care Solutions Deliver Improved Health Outcomes

Teladoc Health, Inc. to Report Q2, 2022 Results on Jul 27, 2022

Jakubowitz Law Reminds Teladoc Shareholders of a Lead Plaintiff Deadline of August 5, 2022

Gainey McKenna & Egleston Files Class Action Lawsuit Against Teladoc Health, Inc

Chief People Officer recently sold €86k worth of stock

Teladoc Health, Inc. Reports Goodwill Impairment for the First Quarter Ended March 31, 2022

First quarter 2022 earnings released: US$41.58 loss per share (vs US$1.31 loss in 1Q 2021)

Teladoc Health, Inc. Appoints Vidya Raman-Tangella as Chief Medical Officer

Teladoc Health, Inc., Annual General Meeting, May 26, 2022

Teladoc Health, Inc. to Report Q1, 2022 Results on Apr 27, 2022

Chief Human Resources Officer recently sold €182k worth of stock

Forecast to breakeven in 2024

Teladoc Health, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2022

Teladoc Health, Inc. Launches “Chronic Care Complete” as First Unified Chronic Condition Management Experience

Teladoc Health, Inc. to Report Q4, 2021 Results on Feb 22, 2022

Teladoc Health, Inc. Provides Revenue Guidance for the Year Ending December 31, 2021

Chief Human Resources Officer recently sold €376k worth of stock

Third quarter 2021 earnings released: US$0.53 loss per share (vs US$0.43 loss in 3Q 2020)

Chief Operating Officer David Sides has left the company